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Abstract
Endometriosis is defined as the growth of endometrial tissue outside of the uterine cavity. The disease occurs
primarily in women of reproductive age but recurrent endometriosis is also detected in post-menopausal women.
Regardless of age, endometriosis is associated with pain and reduces the quality of life for millions of women
world-wide. Conventional therapies focus on reducing systemic levels of estrogen which results in cessation of
endometriotic implant growth and pain symptoms associated with the disease. However, these treatments are not
effective in all women and are not without side effects. Based upon the discovery that endometriotic tissue over-
expresses aromatase, an enzyme critical for estrogen production, emphasis has been placed upon the use of
aromatase inhibitors for the treatment of endometriosis and its associated symptoms. This article will review the
rationale behind the use of aromatase inhibitors in treating endometriosis and summarize those studies which
have evaluated the use of aromatase inhibitors in the treatment of endometriosis and its associated symptoms.
Review
Aromatase and estrogen biosynthesis
Estradiol 17b (or estrogen) is the major biochemical
driving force for endometriotic implant growth. In
women of reproductive age, estrogen is derived primar-
ily from the ovaries and the notion that systemic estro-
gen drives implant growth has long been considered
dogma. However, substantial evidence also points to the
endometriotic implant as an intracrine source of estro-
gen. This locally produced estrogen results from over-
expression of P450 aromatase (referred to hence forth as
aromatase) by endometriotic tissue (Figure 1). As a
result, considerable emphasis has been placed upon the
use of aromatase inhibitors to curtail endometriotic
implant production of estrogen and subsequent implant
growth. The following review highlights the discovery of
endometriotic aromatase expression and the use of aro-
matase inhibitors in the treatment of endometriosis.
Aromatase expression in endometriotic tissue
The first report describing expression of aromatase in
peritoneal endometriotic implants was published in
1996 by Noble and colleagues [1]. Since this initial
report, numerous independent investigators have
described the expression and cellular localization of aro-
matase transcript and protein in endometriotic tissue
[2-8] as well as eutopic endometrium from women with
the disease [2,3,5,8-13]. The majority of these studies
demonstrate that aromatase mRNA can be detected in
most but not all endometriotic biopsies or eutopic endo-
metrial biopsies from women with endometriosis; how-
ever, none of the endometrial biopsies from women
without endometriosis expressed aromatase transcript.
Within endometriotic implants and eutopic endome-
trium from women with endometriosis, aromatase tran-
script expression has been shown to be significantly
greater in epithelial cells compared to stromal cells.
Aromatase protein expression has been localized to
both epithelial and stromal cells of the endometriotic
implant and eutopic endometrium; however, the pattern,
and relative level, of expression within each cell type is
inconsistent. Epithelial cells do appear to be the major
source of endometriotic/endometrial tissue aromatase
protein expression.
While the majority of the literature supports the ele-
vated expression of aromatase in endometriotic tissue, a
recent report by Colette and colleagues [14] refutes the
expression of aromatase in this tissue. In this study,
human peritoneal, ovarian and rectovaginal endometrio-
tic implants as well as matched eutopic endometrial
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mRNA expression. In contrast to previous data, the
findings from this study suggested that aromatase pro-
tein is not expressed in endometriotic tissue or in euto-
pic endometrium from women with the disease and
only low but discernible levels of aromatase transcript
were detected in ovarian endometriomas. The authors
also raise the possibilities that aromatase transcript
expression in ovarian endometriomas may be due to
“contaminating” ovarian tissue and that elevated
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Figure 1 Steroidogenic pathway leading to the production of estradiol. Elevated aromatase (P450 arom) expression by endometriotic
implant tissue is proposed to lead to the local production of estradiol and subsequent implant growth. P450scc = side chain cleavage enzyme;
P450c17 = 17 a-hydroxylase; 3b-HSD = 3b-hydroxysteroid dehydrogenase type 2; 17b-HSD-1 = 17b-hydroxysteroid dehydrogenase type 1.
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from local pelvic cavity tissues such as the peritoneum
or adipose.
While this explanation seems plausible for the discre-
pancy between the study by Colette and colleagues [14]
compared to previous studies evaluating aromatase
expression in endometriotic or endometrial tissue, a
more recent in vitro study [15] supports the notion that
aromatase is indeed expressed in endometriotic and
endometrial cells from women with endometriosis.
Using isolated stromal cells from endometriotic choco-
late cysts and endometrial biopsies, Izawa and colleagues
[15] demonstrated that endometriotic stromal cells
secrete estrogen and that this secretion could be
increased by addition of testosterone to the media.
Further, increased expression of aromatase transcript
was confirmed in the endometriotic cell cultures and
that this expression may be associated with epigenetic
modifications of the aromatase gene. Molecular altera-
tions leading to aberrant aromatase production by endo-
metriotic stromal cells were first reported by Zeitoun
and colleagues [16]. Using isolated stromal cells from
endometriotic and eutopic endometrial tissue, these
investigators demonstrated that the stimulatory tran-
scription factor, SF-1, was over-expressed in endome-
triotic stromal cells compared to stromal cells from
eutopic endometrium. Further, expression of a tran-
scription inhibitory factor, COUP-TF was not expressed
in endometriotic stromal cells but was expressed in stro-
mal cells from eutopic endometrium. As both of these
factors compete for the same cis-acting element, it was
proposed that over-expression of SF-1 coupled with the
absence of COUP-TF in endometriotic stromal cells
leads to expression of aromatase and local estrogen pro-
duction by endometriotic stromal cells.
In summary, the general consensus is that aromatase
transcript and protein are elevated in endometriotic
implants with stromal cells being the major source of
the aberrant expression. Further, there is a great deal of
variability in the expression of aromatase protein in the
eutopic endometrium from women with the disease.
The finding that endometriotic implant aromatase
expression is elevated supports the notion of autono-
mous estrogen production by this tissue. These findings
in turn have lead to the use of aromatase inhibitors in
the medical management of endometriosis.
Aromatase inhibitors in the medical management of
endometriosis
Anastrozole
Anastrozole is a non-steroidal, competitive aromatase
inhibitor which mimics normal enzyme substrate and
competes for binding sites on endogenous aromatase
enzyme [17]. Marketed under the trade name Arimidex
(AstraZeneca), anastrozol has been primary used for
treatment of breast cancer after surgery and for metas-
tases in postmenopausal women. As aromatase has been
proposed to play a role in the pathogenesis of endome-
triosis, its use as a means to treat the disease has
emerged.
The first report describing the use of an aromatase
inhibitor in the treatment of endometriosis was by
Takayama and colleagues [18] in 1998. In that study, a
57-year-old woman who presented with recurrent severe
endometriosis after hysterectomy and bilateral salpingo-
oophorectomy was administered oral anastrozole for 9
months. Anastrozole administration resulted in a signifi-
cant reduction in pelvic pain as well as lesion size in
this patient suggesting that aromatase inhibitors may be
successful candidate drugs in the treatment of endome-
triosis. Additional studies evaluating the efficacy of ana-
strozole in treatment of endometriosis associated pain
have been reported; their findings are discussed below
and are summarized in Table 1.
In 2004, Shippen and West [19] reported treatment of
two pre-menopausal women whom had sought surgical
intervention for severe endometriosis and pain. Both
patients were treated with anastrozole combined with
progesterone, calcitriol and rofecoxib for six repeated
28-day cycles. Treatment resulted in a rapid, progressive
elimination of symptoms over 3 months with the main-
tenance of remission of symptoms for over a year after
treatment in both cases. Treatment was well-tolerated
with no reports of adverse effects. Moreover, pregnancy
was achieved after a year in both cases while in one
case, a follow-up laparoscopy at 15 months after treat-
ment confirmed the absence of disease.
A larger assessment of the effect of anastrozole in
combination with oral contraceptives was conducted by
Amsterdam and co-workers [20] in which fifteen preme-
nopausal patients with documented refractory endome-
triosis and chronic pelvic pain were treated. Women
were administered anastrozole (1 mg) combined with
ethinyl estradiol (20 μg) and levonorgestrel (0.1 mg)
daily for 6 months. Pelvic pain was assessed after each
month while side effects, blood counts and bone density
were monitored. Significant reduction in pelvic pain
scores were noted in 14 of 15 patients and occurred as
early as one month after treatment initiation. Treatment
side effects were mild and improved over time, but
serum estrogen levels were suppressed during treatment.
Although the authors did not provide follow-up assess-
ment to determine if and when symptoms returned after
completion of therapy, these results do suggest that ana-
strozole in combination with oral contraceptives may be
an effective therapy for premenopausal women with
endometriosis which is refractory towards conventional
therapies and who do not wish to conceive.
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analogues in treating endometriosis-associated pain has
also been conducted [21]. Using a prospective, rando-
mized design, eighty patients were randomized to
receive either anastrozole (1 mg/day) plus 3.6 mg of
goserelin or placebo plus goserelin every 4 weeks for 24
weeks. Patients were evaluated for pain at the end of the
24 week treatment period and then again at 6, 12, 18
and 24 weeks after the end of medical treatment. Com-
pared to goserelin alone, co-treatment with anastrozole
significantly increased the pain-free interval (over 2.4
months compared to 1.7 months) and decreased symp-
tom recurrence rates (7.5% recurrence vs. 35% recur-
rence). Anastrozole in combination with goserelin
suppressed serum estrogen levels as well as significantly
reduced greater lumbar spine bone mineral density at
the end of the treatment period compare to the gosere-
lin-only group. However, this was not associated with a
reduction in the menopausal quality of life, and the
bone mineral density lose, although statistically different,
was not determined to be of concern.
The use of anastrozole alone has been reported for the
treatment of rectovaginal endometriosis [22]. Ten pre-
menopausal women were treated with vaginally adminis-
tered anastrozole (0.25 mg in a 2 gram vaginal
suppository) for 6 months. During active treatment, pain
was assessed daily while quality of life was assessed
monthly and these assessments continued for 1 month
after cessation of treatment to provide post-treatment
values. Vaginally administered anastrozole had no effect
on pelvic pain, dyspareunia, number of sexual contacts,
duration and intensity of menstruation during or after
treatment, but dysmenorrhea did improve in all but one
patient. Anastrozole administration did result in
improvement of quality of life, particularly with respect
to physical and social functioning. Also of interest was
the finding that serum estrogen levels were not affected
by anastrozole administration, which, as pointed out by
the authors, may be one reason for the lack of therapeu-
tic efficacy of anastrozole in this study.
An additional, more recent study which evaluated the
use of anastrozole alone was conducted by Verma and
Konje [23]. Three pre-menopausal patients with refrac-
tory endometriosis and chronic pelvic pain were treated
with anastrozole for a 6-month period (while one was
treated with letrozole) after which pelvic pain, serum
estradiol, FSH and LH were assessed in addition to bone
density changes. In all patients, anastrozole (as well as
letrozole) treatment was associated with a significant
reduction in pelvic pain and this occurred independent
of changes in systemic estradiol, LH or FSH levels. Bone
density scores did not differ after treatment. The major
side effect was irregular bleeding. These findings suggest
that anastrozole (and letrozole) is beneficial in premeno-
pausal patients with chronic pelvic pain with minimal
side effects and that these benefits were not associated
with changes in circulating estrogen levels.
Letrozole
Like anastrozole, letrozole (trade name Femera [Novar-
tis]) is also a non-steroidal, competitive aromatase inhi-
bitor which has been used primarily for treatment of
breast cancer [16]. Letrozole has been used alone or in
combination with steroid analogs to treat endometriosis
(summarized in Table 2). The first description of letro-
zole treatment in patients with endometriosis was
reported in 2004. In that study [24], 10 premenopausal
patients with endometriosis were subjected to an open-
label, non-randomized design and were administered
letrozole (2.5 mg daily) in combination with the proges-
tin and norethindrone acetate (2.5 mg) for 6 months.
Pelvic pain, endometriosis stage, bone density and
serum estrogen, LH and FSH were evaluated before and
after treatment administration. Administration of letro-
zole resulted in a significant reduction in pelvic pain
and stage of endometriosis and was not associated with
changes in serum estrogen levels or bone density.
Table 1 Successful use of anastrozole in the treatment of endometriosis associated symptoms
Patient group Summary of Results Reference
Case report
(one post-menopausal patient, recurrent endometriosis)
Rapid decrease in pelvic pain
Decrease in implant mass
[18] Takayama et
al.
Pre-menopausal women (N = 2) (intolerant/failed previous treatment,
severe pain symptoms)
Decrease in associated symptoms
Decrease in implant mass (1 of 2 patients)
[19] Shippen &
West
Pre-menopausal women (N = 15)
(refractory endometriosis, pelvic pain)
Decreased pelvic pain, affect on implant
mass not determined
[20] Amsterdam
et al.
Pre-menopausal women (N = 80)
(prior conservative surgical therapy; N = 40 goserelin vs. N = 40 goserelin
+ anastrozole)
Decreased symptom recurrence rate
Increased pain-free interval
[21] Soysal et al.
Pre-menopausal women (N = 10)
(endometriosis resistant to conventional therapy)
Increased quality of life, decreased
dyspareunia (9/10 patients), change in implant mass
inconclusive
[22] Hefler et al.
Pre-menopausal women (N = 3)
(endometriosis resistant to conventional therapy)
Decreased pelvic pain, affect on implant mass not
determined
[23] Verma &
Konje
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open-label, non-randomized trial consisting of 82 women
with pain symptoms caused by rectovaginal endometrio-
sis. Subjects were administered either letrozole plus nor-
ethisterone actetate or norethisterone acetate alone for 6
months. Changes in pain symptoms as well as side effects
were monitored during the course of treatment and then
again at a 12 month follow-up. At 3 months of treatment,
chronic pelvic pain and deep dyspareunia were signifi-
cantly decreased in both treatment groups compared to
baseline values, while at 6 months, patients treated with
both letrozole and norethisterone reported significantly
less chronic pelvic pain and deep dyspareunia. However,
at 6 months post-treatment, pain symptoms recurred in
both groups. Study subjects also reported lower patient
satisfaction with treatment and a higher percentage of
adverse effects (such as weight gain, joint pain, migranes
and spotting) in the letrozole group. Patients adminis-
tered letrozole in combination with norethisterone acet-
ate experienced a greater reduction in pain during active
treatment, however, the combination therapy was asso-
ciated with a higher cost and incidence of unwanted side
effects and lower patient satisfaction. Based upon these
findings and considering the higher cost of the combina-
tion regimen, the authors concluded that aromatase inhi-
bitors should only be administered to patients who
previously failed to respond to conventional therapies
(such as progestins and/or oral contraceptives) and elect
not to have surgical removal of the disease. Accordingly,
these benefits and drawbacks should be taken into
account when discussing combination letrozole and nor-
ethisterone acetate therapy for women with endometrio-
sis-associated pain.
In 2010, 3 additional small scale studies were con-
ducted evaluating the efficacy of letrozole in the treat-
ment of bladder endometriosis [26], colo-rectal
endometriosis [27] and recurrent ovarian endometrio-
mas [28]. Two premenopausal patients with bladder
endometriosis [26] were treated with letrozole (2.5 mg/
day) and norethisterone actetate (2.5 mg/day) for 6
months. Pain and urinary symptoms were markedly
improved in both patients. After interruption of the 6
month treatment period, one patient developed myalgia
and severe arthralgia and pain and urinary symptoms
returned a few months later while the other patient
reported no adverse effects. In a separate study [27], 6
women with colo-rectal endometriosis who reported
pain and intestinal symptoms were treated with letrozole
(2.5 mg/day) and norethisterone acetate (2.5 mg/day) for
6 months. General pain, non-menstrual pelvic pain, deep
dyspareunia, dyschezia, intestinal cramping and bloating
were improved in all patients, and 4 of the 6 patients
indicated that the treatment improved their gastrointest-
inal symptoms. Letrozole (2.5 mg/day) in combination
with desogestrel (0.15 mg) and ethinyl estradiol (0.03
mg) has been reported to significantly improve pelvic
pain in women with ovarian endometriomas [28]. Treat-
ment of these patients for 6 months with the combina-
tion therapy also induced a complete disappearance of
the endometriomas but no change in bone density.
Table 2 Successful use of letrozole in the treatment of endometriosis associated symptoms
Patient group Summary of Results Reference
Pre-menopausal women (N = 1)
(endometriosis resistant to conventional therapy)
Decreased pelvic pain, affect on implant
mass not determined
[23] Verme
& Konje
Pre-menopausal women (N = 10)
(endometriosis resistant to conventional therapy)
Decrease in pelvic pain
Decrease in implant mass
[24]
Ailawadi et
al.
Pre-menopausal women (N = 82)
(intolerant/failed previous treatment, severe pain symptoms, N = 37 Letrozole +
norethisterone acetate vs. N = 38 Norethisterone acetate alone)
Decrease in pelvic pain and deep
dyspareunia, affect on implant mass
unknown
[25] Ferrero
et al.
Pre-menopausal women (N = 2)
(bladder endometriosis, non-responsive to conventional therapy, pelvic pain and urinary
symptoms)
Decreased pelvic pain and urinary
symptoms, affect on implant mass not
determined
[26] Ferrero
et al.
Women with colorectal endometriosis
(N = 6; pain and intestinal symptoms)
Decreased pain and intestinal symptoms,
affect on implant mass unknown
[27] Ferrero
et al.
Pre-menopausal women (N = 5)
(recurrent ovarian endometriosis, chronic pelvic pain)
Decreased pelvic pain, decreased implant
mass
[28] Lall et
al.
Pre-menopausal women (N = 1)
(recurrent endometriosis resistant to conventional therapy, pelvic pain dyspareunia)
Decreased pelvic pain and dyspareunia,
affect on implant mass not determined
[29] Razzi et
al.
Post-menopausal woman (N = 1)
(recurrent endometrioma, pain)
Decreased pain, decrease in implant mass [30] Fatemi
et al.
Post-menopausal woman (N = 1)
(severe pelvic pain)
Decreased pelvic pain, affect on implant
mass unknown
[31] Mousa
et al.
Post-menopausal woman (N = 1)
(recurrent abdominal wall endometriosis)
Decreased implant mass [32] Sasson
& Taylor
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alone [29] or in combination with steroids [29-31] is
effective in treatment of endometriosis-associated pelvic
pain. Razzi and colleagues [29] reported that a 31 year
old woman with recurrent endometriosis after subtotal
hysterectomy with bilateral oophorectomy who was
administered letrozole alone (2.5 mg) showed significant
reduction in pelvic pain and dyspareunia during the 6
months of treatment with no adverse impact on bone
density. Similar positive outcomes using letrozole in
combination with progestins were noted in a post-
menopausal patient with recurrent endometrioma [30]
and in a middle-aged woman with endometriosis and
severe pelvic pain after hysterectomy and bilateral sal-
pingo-oophorectomy [31]. More recently, Sasson and
Taylor [32] reported the case of a post-menopausal
woman with a large, recurrent abdominal wall endome-
trioma who was successfully treated with letrozole (5
mg) and medroxyprogesterone acetate.
While the majority of the literature suggests that
letrozole may be effective in treating patients with endo-
metriosis, not all clinical trials using letrozole were suc-
cessful. An open-label prospective study in 2007 [33]
reported that letrozole (2.5 mg/day) combined with nor-
ethisterone acetate (2.5 mg/day) quickly reduced the
intensity of symptoms related to the presence of recto-
vaginal endometriosis. However, pain recurred at 3-
month follow-up. Five of the initial 12 women treated,
underwent surgery during the follow-up, and histologi-
cal examination of rectovaginal nodules revealed the
presence of active endometriotic lesions. In another
open-label prospective study [34], 12 women with stage
IV refractory endometriosis were treated with letrozole
(2.5 mg) and desogestrel (75 μg). Unfortunately, all 12
patients developed ovarian cysts and were unable to
complete the scheduled six-month treatment regime.
However, at the interruption of treatment, all women
reported significant improvements in dysmenorrhea and
dyspareunia, but pain symptoms quickly recurred at 3-
month follow up.
Aromatase inhibitors and fertility restoration in women
with endometriosis
The majority of studies and trials evaluating the use of
aromatase inhibitors in women with endometriosis have
focused on relief of pelvic pain and/or effect on endo-
metriotic implant size/severity of disease. However, one
recent pilot study conducted by Lossl and colleagues
[35] concurrently evaluated the effect of anastrazole
(coupled with goserelin) on endometriomal volume,
CA125 levels and standard IVF (in vitro fertilization)
fertility parameters. Twenty women with endometriosis
undergoing IVF/ICSI were treated with goserelin (3.6
mg s.c.) on treatment days 1, 28 and 56 and anastrazole
(1 mg daily) from days 1 to 69 of the study, with ovarian
stimulation occurring on day 70. Both endometriomal
volume and CA125 levels (as a marker of endometrioma
activity) decreased by 29% and 61%, respectively during
the combined down-regulation. The average number of
oocytes retrieved was 7.5 and the fertilization rate was
78%. Nine of the twenty patients conceived while five of
these had clinical pregnancies with three of them deli-
vering healthy offspring. This study demonstrated that
combined anastrazole and goserelin down-regulation
markedly reduces endometriomal volume and disease
activity which is compatible with pregnancy and deliv-
ery. Concern was expressed with the rate of pregnancy
loss (from 5 chemical pregnancies to 3 patients deliver-
ing) but it should be emphasized that larger, controlled
studies must be conducted to further evaluate this initial
observation. This contention is supported by a recent
report [36] in which 159 infertile women undergoing
controlled ovarian stimulation and artificial insemination
treated with the aromatase inhibitor, letrozole in combi-
nation with FSH, exhibited comparable pregnancy rates
with less cancelled cycles and less FSH required for sti-
mulation compared to FSH-treated patients alone.
Use of aromatase inhibitors in animal models of
endometriosis
In addition to human trials, animal studies have also
evaluated aromatase inhibitors in the treatment of endo-
metriosis and support the notion that inhibition of
endometriotic implant aromatase activity leads to reduc-
tion in endometriotic implant mass. Aromatase has
been shown to be expressed in endometriotic implants
of mice with experimentally-induced endometriosis [37].
Mice with experimentally-induced endometriosis in
which the expression of aromatase has been genetically
disrupted exhibit significantly smaller endometriotic
implants [38] validating the use of such animal models.
I nas i d eb ys i d ec o m p a r i s o n[ 3 7 ] ,b o t ha n a s t r o z o l e
and letrozole significantly decreased endometriotic
implant size in mice with experimentally-induced endo-
metriosis. Both aromatase inhibitors decreased cell pro-
liferation, but the impact on cell apoptosis was time-
dependent with respect to time of intervention after dis-
ease establishment. Lastly, both anastrozole and letro-
zole decreased peritoneal fluid vascular endothelial cell
growth factor levels while only anastrozole decreased
peritoneal fluid PGE levels.
The effect of anastrozole on experimental endometrio-
sis in rats has also been evaluated. Alintas and collea-
gues [39] conducted a randomized, placebo-controlled,
single-blind study comparing the effect of anastrozole
and raloxifene on endometriotic implant volume (size)
after 8 weeks of treatment. The authors found that,
compared to placebo, both anastrozole and raloxifene
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triotic implant volume. No difference was detected in
implant size between the two drugs.
The efficacy of letrozole in endometriosis treatment
has also been examined in rats with surgically-induced
endometriosis [40]. In this study by Oner and collea-
gues, rats with surgically-induced endometriosis were
randomly assigned to receive either one of two doses of
metformin (100 or 200 mg/kg/day), letrozole (0.1 mg/
kg/day) or placebo for 4 weeks after which endometrio-
tic implant size and pelvic adhesions were determined.
Metformin (both doses) and letrozole caused a signifi-
cant reduction in endometriotic implant size. While
letrozole did not affect pelvic adhesion, metformin
reduced the severity of pelvic adhesions irrespective of
dose.
Collectively, these studies demonstrate that letrozole
and anastrozole are effective in reducing endometriotic
implant size in rodents with experimentally-induced
endometriosis. The use of these and other genetically
modified mice (tissue-specific aromatase knockout or
over-expression) coupled with the use of aromatase
inhibitors should allow for a thorough dissection of the
mechanisms by which these inhibitors work to induced
endometriotic implant regression.
Conclusions
The majority of the evidence in the literature supports
the notion that aromatase expression is elevated in
human endometriotic tissue, and this concept is further
supported in studies using animal models for the dis-
ease. Based upon this expression, it has been proposed
that elevated aromatase activity in endometriotic tissue
leads to local estrogen production and endometriotic
lesion growth which is associated with disease symptoms
such as pelvic pain. Not surprising, reduction of aroma-
tase activity by aromatase inhibitors has been associated
with reduced endometriotic lesion size in both animal
models and in human studies. In human subjects, aro-
matase alone, or in combination with steroids, appears
to be effective in reduction of endometriosis-associated
symptoms such as pelvic pain. Aromatase inhibitors
appear to be most beneficial in the treatment of endo-
metriosis in women with recurrent endometriosis who
have not had success with more conventional treatment
regimes such as gonadtropin releasing agonists/antago-
nists or steroidal analogues. However, one must keep in
mind that aromatase inhibitors exhibit suboptimal toler-
ability and greater costs compared to some of the more
conventional therapies. Clearly, aromatase inhibitor
therapy may have a place in endometriosis treatment of
a subset of patients suffering from the disease and bene-
fits and limitations of these compounds must be dis-
cussed with patients. Future effort should be directed
towards performing larger, multi-center trials with aro-
matase inhibitors to provide a more robust assessment
of the efficacy of these compounds in the treatment of
endometriosis and its associated symptoms.
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